Glycemia and Coagulation in Patients with Glioblastomas

Area of Science:

• Neuro-oncology
• Hematology
• Oncology

Background:

• Glioblastomas are aggressive brain tumors with poor prognoses.
• Coagulation system perturbations, including neoangiogenesis and thromboembolism risk, are common in glioblastomas.
• Hyperglycemia is a known prothrombotic factor, yet its role in neuro-oncology is understudied.

Purpose of the Study:

• To investigate the relationship between glycated hemoglobin (HbA1c) and coagulation markers in patients with de novo intracranial glioblastomas.
• To explore the potential link between hyperglycemia and coagulation dysregulation in the context of brain tumors.

Main Methods:

• Analysis of 74 patients with intracranial glioblastomas from three hospitals.
• Correlation analysis between HbA1c levels and routine coagulation markers: D-dimers, prothrombin time, and activated partial thromboplastin time (aPTT).
• Assessment of Ki67 immunoreactivity in relation to coagulation markers.

Main Results:

• A significant inverse correlation was observed between HbA1c and aPTT (ρ = -0.379; P = 0.0009).
• A significant inverse correlation was found between Ki67 immunoreactivity and aPTT (ρ = -0.211; P = 0.0082).
• No significant correlation was found between HbA1c and D-dimers or prothrombin time.

Conclusions:

• Hyperglycemia and more proliferative glioblastomas may significantly disrupt coagulation profiles, primarily via the intrinsic pathway.
• These findings underscore the clinical importance of understanding the interplay between hyperglycemia, glioblastoma, and coagulation.
• Further research is warranted to elucidate this connection and inform therapeutic strategies against glioblastoma.